Ovid Therapeutics Inc (NASDAQ: OVID) on Monday, plunged -7.30% from the previous trading day, before settling in for the closing price of $1.78. Within the past 52 weeks, OVID’s price has moved between $0.24 and $2.01.
A company in the Healthcare sector has jumped its sales by 24.72% annually for the last half of the decade. The company achieved an average annual earnings per share of -27.87%. With a float of $58.32 million, this company’s outstanding shares have now reached $71.15 million.
Ovid Therapeutics Inc (OVID) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ovid Therapeutics Inc is 18.10%, while institutional ownership is 71.73%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.13 earnings per share (EPS) for the period topping the consensus outlook (set at -0.17) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.20% during the next five years compared to 24.72% growth over the previous five years of trading.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Ovid Therapeutics Inc (OVID) is currently performing well based on its current performance indicators. A quick ratio of 4.24 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Let’s dig in a bit further. During the last 5-days, its volume was 2.08 million. That was better than the volume of 1.53 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 76.88%.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 76.16%, which indicates a significant increase from 62.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1269 in the past 14 days, which was lower than the 0.1340 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5093, while its 200-day Moving Average is $0.8724. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $1.7133. Second resistance stands at $1.7767. The third major resistance level sits at $1.8283. If the price goes on to break the first support level at $1.5983, it is likely to go to the next support level at $1.5467. The third support level lies at $1.4833 if the price breaches the second support level.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
Market capitalization of the company is 117.50 million based on 71,212K outstanding shares. Right now, sales total 570 K and income totals -26,430 K. The company made 130 K in profit during its latest quarter, and -12,160 K in sales during its previous quarter.
